Evidence map›Paper›PMID 42031964›Full record

ArticleNPJ precision oncology2026

Deep learning for predicting pituitary neuroendocrine tumour lineage and high-risk subtypes from histology.

Anli Zhang, Fang Zhao, Daizhong Wang, Chong Ge, Jun Xu, Xuhao Tian, Lanqing Cheng, Wei Wang, Zunguo Du, Ao Li and 3 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anli Zhang *Department of Pathology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Fang Zhao *The School of Information Science and Technology, University of Science and Technology of China, Hefei, Anhui, China.
Daizhong Wang *Department of Pathology, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Chong GeDepartment of Pathology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Jun XuDepartment of Pathology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Xuhao TianThe School of Information Science and Technology, University of Science and Technology of China, Hefei, Anhui, China.
Lanqing ChengDepartment of Pathology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Wei WangDepartment of Pathology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Zunguo DuDepartment of Pathology, Huashan Hospital, Fudan University, Jing'an District, Shanghai, China.
Ao LiThe School of Information Science and Technology, University of Science and Technology of China, Hefei, Anhui, China. aoli@ustc.edu.cn.
Ji XiongDepartment of Pathology, Huashan Hospital, Fudan University, Jing'an District, Shanghai, China. dabenx@163.com.
Minghui WangThe School of Information Science and Technology, University of Science and Technology of China, Hefei, Anhui, China. mhwang@ustc.edu.cn.
Haibo WuDepartment of Pathology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China. wuhaibo@ustc.edu.cn.

Funding

Anhui Provincial Natural Science Foundation 2308085MF191Medical Artificial Intelligence Joint Fund MAI2023C014
6 · The paper itself

Abstract

Pituitary neuroendocrine tumours (PitNETs) exhibit significant heterogeneity, posing challenges for clinical management. We developed a deep learning model to predict PitNET lineage, high-risk subtypes, and recurrence directly from routine H&E-stained whole-slide images. Trained on 925 patients from USTC and externally validated on cohorts from Taihe Hospital (n = 226) and Huashan Hospital (n = 193), the model achieved a micro-average AUC of 0.912 for lineage classification (SF1: 0.926, PIT1: 0.932, TPIT: 0.904; Without distinct lineage: 0.706). High-risk subtype prediction yielded AUCs of 0.805 (PIT1), 0.753 (TPIT), and 0.733 (null cell). Recurrence prediction reached an AUC of 0.641. Analysis of the tumour microenvironment revealed that compared with primary tumours, recurrence tumours were characterized by an increased density of M2 macrophages and decreased infiltration of CD8 + T cells. Spatial transcriptomics further elucidated distinct molecular pathways associated with recurrence, providing mechanistic insights into prognostic predictions. Our deep learning model accurately predicts PitNET characteristics from routine H&E slides, and spatial biology validation identified distinct immune and molecular features associated with recurrence.

Identifiers

PMID42031964
PMCPMC13320157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.